FDA Clearance Tracker · P170019-S021
FoundationOne CDx (F1CDx)
Last checked: Nov 20, 2026Latest source record: May 28, 2021 (this decision)Source: openFDAMethods & limitations
Decided
May 28, 2021
Approved
Time to decision
211 days
Received Oct 29, 2020. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P170019-S021
- Device name
- FoundationOne CDx (F1CDx)
- Applicant
- Foundation Medicine, Inc.
- Applicant location
- Boston, MA
- Received
- Oct 29, 2020
- Decided
- May 28, 2021
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P170019
Device type
- Device type
- Next generation sequencing oncology panel, somatic or germline variant detection system (PQP)
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval to expand the intended use of FoundationOne CDx (F1CDx) to include a companion diagnostic indication for FGFR2 fusion/rearrangements in patients with Cholangiocarcinoma who may benefit from treatment with Truseltiq (infigratinib).
Source documents
Other decisions for Foundation Medicine, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- FoundationOne CDx (F1CDx)PMA supplement
P170019-S060 · Decided May 27, 2026 · 614 days after receipt · Panel Track
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.